PolyPid (NASDAQ:PYPD) said its first quarter marked a transition from late-stage clinical development toward regulatory submission and commercial preparation for D-PLEX100, its lead product candidate for preventing surgical site infections in abdominal colorectal surgery.
Chief Executive Officer Dikla Czaczkes Akselbrad told investors that the company’s priorities are advancing D-PLEX100 toward potential U.S. Food and Drug Administration approval and finalizing a U.S. strategic partnership intended to support a commercial launch in the first quarter of 2027.